Abstract
Background:
Anticoagulant therapy is indispensable for thromboembolism management, yet it presents an inherent pharmacological paradox by elevating the risk of catastrophic hemorrhage. Navigating this dynamic hemostatic equilibrium remains a profound clinical challenge.
Pharmacological landscape:
This review systematically evaluates the evolution of procoagulant strategies. While specific reversal agents (e.g., idarucizumab, andexanet alfa) have inaugurated an era of targeted precision reversal through high-affinity molecular neutralization, their widespread application is frequently hampered by exorbitant pharmacoeconomic costs, limited accessibility, and latent prothrombotic “off-target” effects (e.g., TFPI inhibition). Conversely, non-specific agents, epitomized by four-factor prothrombin complex concentrate (4F-PCC) and adjunctive antifibrinolytics, retain a foundational, highly cost-effective role in real-world rescue paradigms.
Technological innovations:
To circumvent existing limitations, current technological trajectories are pivoting towards the rational design of broad-spectrum synthetic molecules (e.g., ciraparantag) and highly programmable nucleic acid aptamer systems. These innovations promise to deliver “on-demand” reversibility and democratize access to hemostatic therapies.
Clinical management & perspectives:
Translating these pharmacological breakthroughs into optimal patient outcomes necessitates a paradigm shift in clinical workflows. We propose a multidimensional framework driven by point-of-care (POC) viscoelastic testing, algorithmic clinical decision support systems, and sequential therapy pathways managed by multidisciplinary “Code Bleed” teams. Future research must urgently prioritize large-scale, head-to-head randomized trials focused on patient-centered hard endpoints, ultimately refining evidence-based strategies to maximize therapeutic efficacy while strictly mitigating thrombotic risks.
1 Introduction
Anticoagulant therapy is indispensable for stroke prevention in atrial fibrillation (AF) and the management of venous thromboembolism (VTE) (). However, by interfering with the coagulation cascade to reduce thrombotic burden, these agents inevitably compromise physiological hemostasis, thereby elevating bleeding risk (). This inherent pharmacological paradox constitutes the central dilemma of anticoagulation management.
Current anticoagulants fall into three broad categories. Vitamin K antagonists (VKAs), such as warfarin, inhibit the synthesis of vitamin K-dependent coagulation factors; their clinical utility is constrained by substantial interindividual variability and the requirement for frequent INR monitoring. Direct oral anticoagulants (DOACs)—comprising the direct thrombin inhibitor dabigatran and the factor Xa inhibitors rivaroxaban, apixaban, and edoxaban—target specific components of the coagulation cascade, offering predictable pharmacokinetics without the need for routine coagulation monitoring (). Parenteral agents, including unfractionated heparin (UFH), low-molecular-weight heparin (LMWH), and fondaparinux, are reserved for initial therapy or scenarios where oral administration is unfeasible ().
Bleeding risk remains the pervasive concern throughout anticoagulant therapy (Table 1). The International Society on Thrombosis and Haemostasis (ISTH) has standardized bleeding events into major bleeding and clinically relevant non-major bleeding (CRNMB), enabling unified severity assessment and stratified management. Bleeding profiles differ markedly across anticoagulant classes: warfarin carries a relatively high risk of intracranial hemorrhage (ICH), closely linked to INR stability, whereas DOACs reduce ICH risk by approximately 50% yet increase gastrointestinal (GI) bleeding, particularly with dabigatran and rivaroxaban (). Therapeutic challenges in special populations—including patients with renal impairment, the frail elderly, and obesity, where altered drug distribution volumes and clearance rates complicate DOAC dosing—further compound management complexity (). Drug-drug interactions and the clinical paradox arising from the absence of routine DOAC monitoring add additional layers of difficulty.
Table 1
| Drug category | Representative agents | Key target/mechanism | Monitoring requirement | Characteristic bleeding risk |
|---|---|---|---|---|
| Traditional oral anticoagulants (VKAs) | Warfarin | Inhibits synthesis of vitamin K-dependent factors (II, VII, IX, X) | Routine INR monitoring mandatory | High inter-individual variability; elevated ICH risk, closely INR-dependent |
| Direct thrombin inhibitor (DTI) | Dabigatran | Directly inhibits factor IIa (thrombin) | No routine monitoring | ≈50% lower ICH vs. warfarin; significantly increased GI bleeding |
| Factor Xa inhibitor | Rivaroxaban, Apixaban, Edoxaban | Direct inhibition of factor Xa | No routine monitoring | Increased GI bleeding (especially rivaroxaban); lower ICH vs. warfarin |
| Parenteral anticoagulants | UFH, LMWH, Fondaparinux | ATIII-mediated inhibition of IIa and/or Xa | Drug-dependent (aPTT/anti-Xa) | Insufficient effect → thrombosis; excessive effect → bleeding |
Overview of the mechanisms of action and bleeding risk characteristics of mainstream anticoagulants.
*ICH, intracranial hemorrhage; GI, gastrointestinal; VKAs, vitamin K antagonists; INR, international normalized ratio; UFH, unfractionated heparin; LMWH, low-molecular-weight heparin; ATIII, antithrombin III.
When anticoagulant-induced bleeding occurs, or when intrinsic coagulopathy substantially elevates hemorrhagic risk, the rational deployment of procoagulant or specific reversal agents becomes a critical component of clinical decision-making () (Figure 1).
Figure 1
In the present review, we provide a comprehensive synthesis of current evidence on the pharmacological management of anticoagulant-associated bleeding, encompassing both specific reversal agents and non-specific hemostatic strategies, as well as emerging technologies and clinical decision-making frameworks. This is a narrative review rather than a systematic review. The literature search was conducted in PubMed and Embase for articles published in English from January 2000 to December 2025, using combinations of key terms including “anticoagulant reversal,” “procoagulant agents,” “andexanet alfa,” “idarucizumab,” “prothrombin complex concentrate,” “tranexamic acid,” “protamine,” “ciraparantag,” “aptamer anticoagulant reversal,” and “anticoagulant-associated bleeding management.” Reference lists of retrieved articles and relevant clinical practice guidelines were also manually screened for additional sources. Given the narrative nature of this review, no formal quality assessment or quantitative synthesis was performed; rather, we aimed to provide a clinically oriented, critical appraisal of the evolving therapeutic landscape.
2 The hemostatic armamentarium: mechanism-driven pharmacology and clinical positioning
When anticoagulant-induced hemorrhage occurs, clinicians must navigate a diverse arsenal of hemostatic agents with distinct mechanisms, specificities, and safety profiles. These agents can be broadly divided into specific reversal agents—designed to neutralize individual anticoagulants through high-affinity molecular interactions—and non-specific hemostatic agents, which restore hemostasis through broader, pleiotropic mechanisms. The following sections examine each category in turn, with an emphasis on the practical indications, contraindications, and risk-benefit assessments that inform bedside decision-making.
2.1 General principles of procoagulant use: indications, contraindications, and risk-benefit assessment
Procoagulant and hemostatic agents are pharmacological therapies that arrest bleeding by accelerating the coagulation cascade or reducing capillary permeability (). They are indicated for hemorrhagic disorders driven by coagulation factor deficiencies, platelet abnormalities, or hyperfibrinolysis. Within anticoagulant therapy, their clinical positioning encompasses three principal dimensions. First, they serve as targeted interventions for reversing excessive anticoagulation in the setting of acute hemorrhage. Second, they act as prophylactic hemostatic measures in patients with clear anticoagulation indications who nonetheless carry elevated bleeding risk, thereby maintaining a dynamic equilibrium between thrombotic and hemorrhagic tendencies (). Third, they provide bridging reversal prior to emergent surgery or invasive procedures, mitigating the risk of iatrogenic hemorrhage while enabling necessary interventions to proceed safely.
The application of procoagulant agents demands strict adherence to a rigorous risk-benefit framework (). In patients requiring long-term anticoagulation, inappropriate procoagulant administration can negate established antithrombotic benefits and, critically, precipitate iatrogenic thrombotic events. Consequently, clinical deployment requires highly individualized decision-making aimed at accurately identifying the precise balance between hemostatic needs and thrombotic risks—a logic that mirrors the fundamental objectives of anticoagulant therapy itself.
2.2 Targeted specific reversal agents: the rise and fall of a paradigm
Specific reversal agents are designed on the principle of precision targeting: by binding with high affinity directly to an anticoagulant molecule or its target, they sterically block its interaction with endogenous coagulation factors, thereby restoring physiological hemostasis without broadly activating the coagulation cascade. This targeted approach promised an era of elegant pharmacological solutions to anticoagulant-associated bleeding. However, as the contrasting fates of andexanet alfa and idarucizumab illustrate, molecular precision alone does not guarantee clinical safety, nor does surrogate laboratory reversal reliably translate into improved patient outcomes.
2.2.1 Anti-factor Xa decoys: the cautionary tale of andexanet alfa
Andexanet alfa () represented a landmark in targeted anticoagulant reversal: a genetically engineered, recombinant modified human factor Xa decoy protein designed to neutralize factor Xa inhibitors with high specificity. Its structural design (Figure 2) exemplified the principles of precision pharmacology through two critical site-directed mutations (). First, a mutation at the serine active site rendered it catalytically inert. Second, a mutation within the membrane-binding γ-carboxyglutamic acid (Gla) domain prevented its incorporation into the prothrombinase complex. These modifications abolished its capacity to participate in the endogenous coagulation cascade while fully preserving the high-affinity binding pocket for factor Xa inhibitors, creating a decoy receptor that competitively sequestered circulating inhibitors—including rivaroxaban, apixaban, and edoxaban—and restored thrombin generation (). Intravenous administration rapidly diminished anti-factor Xa activity within minutes, although its effective half-life was notably short at approximately one hour, necessitating a continuous infusion following the initial bolus ().
Figure 2
The clinical promise of andexanet alfa was initially supported by the ANNEXA-4 trial, a pivotal Phase III multicenter study demonstrating a 92% reduction in median anti-factor Xa activity and an 82% rate of good or excellent hemostatic efficacy at 12 h in patients with factor Xa inhibitor-associated major bleeding (, ). These findings provided the evidentiary foundation for regulatory approval. However, the subsequent ANNEXA-I randomized controlled trial—designed to evaluate clinical superiority over usual care—ultimately reversed the narrative. An interim analysis revealed that although andexanet alfa was superior in controlling hematoma expansion in patients with intracranial hemorrhage, it was associated with a significantly higher 30-day incidence of thrombotic events (10% vs. 5.6% in the control group), with no confirmed improvement in long-term functional outcomes or all-cause mortality (, ).
This thrombotic signal was not incidental but mechanistically rooted. Beyond neutralizing factor Xa inhibitors, andexanet alfa binds with high affinity to tissue factor pathway inhibitor (TFPI), a critical endogenous negative regulator of the extrinsic coagulation pathway. Inhibition of TFPI removes a key brake on the tissue factor–factor VIIa (TF-FVIIa) complex, triggering unregulated thrombin generation—a so-called “thrombin storm”—that mediates a systemic prothrombotic state. This off-target physiological effect, inherent to the decoy molecule's structure, ultimately led to the agent's withdrawal from the market.
The case of andexanet alfa thus serves as a definitive cautionary tale. It demonstrates that exquisite molecular targeting does not guarantee clinical safety, and that surrogate laboratory endpoints (anti-Xa activity reduction) do not reliably translate into patient-centered outcomes. Its legacy underscores the imperative of rigorous safety evaluation against hard clinical endpoints before targeted reversal agents assume a routine place in clinical care.
2.2.2 Anti-thrombin antibodies: the sustained success of idarucizumab
Dabigatran, a direct thrombin inhibitor, is among the most widely prescribed DOACs (), valued for its predictable pharmacokinetics, lower ICH risk relative to warfarin, and lack of routine coagulation monitoring. Multiple international guidelines recommend it as first-line therapy for stroke prevention in non-valvular atrial fibrillation and for VTE management (, ). In the settings of life-threatening major bleeding or urgent invasive procedures, rapid reversal of its anticoagulant effect remains a critical clinical necessity ().
Idarucizumab () is a humanized monoclonal antibody fragment (Fab) specifically engineered to bind dabigatran with high affinity—approximately 350 times greater than dabigatran's affinity for thrombin—and essentially irreversible specificity (Figure 2). Through competitive displacement (), it rapidly uncouples dabigatran from the active site of thrombin, forming a stable, biologically inactive complex that reinstates the physiological coagulation cascade. Idarucizumab exhibits no cross-reactivity with endogenous thrombin, other coagulation factors, or non-targeted anticoagulants (). Critically, the antibody fragment is devoid of intrinsic procoagulant activity (), meaning it does not independently trigger clot formation.
The landmark RE-VERSE AD trial—a global, multicenter, single-arm Phase III study enrolling 503 dabigatran-treated patients (301 with life-threatening major bleeding; 202 requiring urgent procedures)—demonstrated complete anticoagulant reversal within minutes of a 5 g intravenous infusion (, ). Hemostasis was achieved in 93% of the urgent surgery cohort. The 30-day thromboembolic event rate was 4.8%, with the vast majority occurring in patients who had not yet reinitiated baseline anticoagulation—underscoring that reversal itself restores the patient's underlying thrombotic predisposition rather than reflecting an intrinsic prothrombotic effect of the antibody. Subsequent neurosurgical subgroup analyses () and the real-world RE-VECTO registry (n = 359) further corroborated its hemostatic efficacy, with only 1.7% requiring a second dose (). Based on this evidence, guidelines from the ISTH and ACC/AHA unanimously recommend idarucizumab as the first-line reversal strategy for dabigatran-associated life-threatening bleeding and for pre-procedural reversal (). It remains the only DOAC-specific reversal agent approved for urgent surgical interventions in non-bleeding patients ().
Clinically, idarucizumab is administered as a fixed 5 g intravenous dose, delivered as two consecutive 2.5 g boluses no more than 15 min apart (, ). Dose adjustment is unwarranted for age, hepatic, or renal function (); although renal impairment may prolong the terminal half-life, reversal efficacy remains uncompromised (). Given its exquisite target specificity, idarucizumab neutralizes only dabigatran and has no reversal effect on factor Xa inhibitors or VKAs; thus, definitive confirmation of dabigatran use is a prerequisite (). For laboratory monitoring, ECT and dTT serve as the recommended quantitative assays, while aPTT provides only a qualitative, supplementary indicator ().
2.2.3 Classical reversal agents: protamine and vitamin K
Vitamin K: Vitamin K serves as the specific antidote for warfarin (, ), which exerts its anticoagulant effect by inhibiting vitamin K epoxide reductase (VKOR), thereby blocking the recycling of vitamin K and impairing the γ-carboxylation of vitamin K-dependent coagulation factors (II, VII, IX, X) (, ). Exogenous vitamin K restores hepatic synthesis of functional coagulation factors, reversing the anticoagulant effect at its molecular source (). Onset of action is route-dependent: intravenous infusion initiates reversal within 4–6 h (), whereas oral administration is delayed to approximately 24 h, with complete reversal often requiring several days (). Clinically, vitamin K is indicated for patients with supratherapeutic INRs and significant bleeding. For life-threatening major hemorrhage, international guidelines recommend co-administration with 4F-PCC to achieve both rapid hemostasis and sustained reversal.
Protamine Sulfate: Protamine sulfate () is the specific antagonist for heparin-based anticoagulants (). A strongly basic cationic polypeptide originally isolated from salmon sperm (), protamine neutralizes heparin within minutes through electrostatic binding to highly acidic heparin molecules, forming stable, biologically inactive complexes. Heparins function by binding to antithrombin III (ATIII), accelerating its inhibition of thrombin and factor Xa (, ). Protamine's reversal efficacy is molecular-weight-dependent: it achieves approximately 100% neutralization of UFH, yet only approximately 60% neutralization of LMWH (, ), owing to the shorter polysaccharide chains of LMWH that offer fewer protamine-binding sites and preferential anti-Xa activity (50).
Critically, protamine itself exhibits dose-dependent anticoagulant activity in the absence of heparin. Therefore, its administration must be predicated upon clear documentation of recent heparin exposure and the time of the last dose. Additional safety concerns include hypersensitivity reactions—patients with fish allergy, prior protamine exposure, or prior use of protamine-containing insulin (e.g., NPH insulin) are at elevated risk (51)—and severe cardiovascular complications (hypotension, bradycardia) associated with rapid intravenous infusion (52). In summary, vitamin K provides slow-onset but sustained reversal targeting upstream factor synthesis, ideally in combination with PCC for major warfarin-associated bleeding; protamine offers rapid, chemical neutralization of UFH and partial reversal of LMWH, but demands rigorous patient selection given its paradoxical anticoagulant potential in the absence of circulating heparin (Table 2).
Table 2
| Agent | Targeted anticoagulant(s) | Mechanism | Dosage regimen | Key Advantages | Limitations/safety risks |
|---|---|---|---|---|---|
| Idarucizumab | Dabigatran (DTI) | Humanized Fab fragment; high-affinity, essentially irreversible binding to dabigatran, competitively blocking thrombin inhibition | Fixed 5 g IV, as two 2.5 g boluses ≤15 min apart | Rapid onset; no intrinsic procoagulant activity; no dose adjustment for hepatic or renal impairment | Effective only against dabigatran; no reversal of other anticoagulant classes |
| Vitamin K | Warfarin (VKA) | Restores hepatic synthesis of functional vitamin K-dependent factors (II, VII, IX, X) | IV or oral; dose titrated to INR | Prolonged duration of action; extremely low cost; flexible administration routes | Slow onset (4–6 h IV; ∼24 h oral); cannot be used as monotherapy for life-threatening major bleeding |
| Protamine Sulfate | UFH; LMWH (partial) | Strongly basic polypeptide; neutralizes acidic heparin molecules via electrostatic binding, blocking ATIII-mediated anticoagulation | IV bolus; dose matched 1:1 to total heparin administered | Ultra-rapid onset (within 5 min); 100% neutralization of UFH | Only ∼60% neutralization of LMWH; no activity against fondaparinux; risk of hypersensitivity reactions; paradoxical anticoagulant effect in the absence of circulating heparin—administration requires confirmed recent heparin exposure and last dose timing |
Comprehensive information comparison of specific reversal agents.
Note on Andexanet Alfa: Andexanet alfa, a modified recombinant factor Xa decoy receptor, was previously approved for reversal of direct factor Xa inhibitors (rivaroxaban, apixaban). However, the ANNEXA-I trial demonstrated a significantly increased 30-day thrombotic event rate (10% vs. 5.6%) attributed in part to off-target TFPI inhibition, and the agent has subsequently been withdrawn from the market. It is therefore excluded from the current table of clinically available agents. See Section 2.2.1 for a detailed discussion of its mechanism and the safety concerns that led to its withdrawal.
2.3 Non-specific hemostatic agents: the reigning workhorses
Despite the conceptual appeal of targeted reversal, practical constraints—limited availability, prohibitive cost, and, in the case of andexanet alfa, unacceptable thrombotic risk—have relegated specific agents to a narrow set of clinical scenarios. In the majority of anticoagulant-associated bleeding emergencies, non-specific hemostatic agents remain the cornerstone of management. These agents restore hemostasis through broad mechanisms: replenishing coagulation substrates, inhibiting fibrinolysis, or stabilizing vascular integrity. The following sections examine the hierarchy of non-specific options, emphasizing the evidence, indications, and safety considerations that guide their clinical use.
2.3.1 Factor concentrates and plasma: a hierarchy of choice
Coagulation factor concentrates are the cornerstone of non-specific hemostatic therapy for anticoagulant-associated major bleeding, particularly when specific reversal agents are unavailable or the offending anticoagulant is unidentified (53, 54). The three principal formulations—4F-PCC, aPCC, and FFP—differ markedly in composition, efficacy, and safety (55), mandating a clear hierarchy of clinical selection.
Four-Factor Prothrombin Complex Concentrate (4F-PCC) is the most widely utilized standardized factor concentrate (56). Comprising vitamin K-dependent factors (II, VII, IX, X) balanced with the physiological anticoagulants protein C and protein S (57), 4F-PCC bypasses the coagulation steps blocked by anticoagulants, directly restoring thrombin generation (58). In factor Xa inhibitor-associated major bleeding, Observational data suggest hemostatic efficacy rates of 65%–89% for 4F-PCC in factor Xa inhibitor-associated major bleeding, though these estimates derive from small, single-arm studies and high-quality randomized evidence is lacking. The reported 30-day thromboembolic event rate is 3%–8% (59, 60). Its therapeutic cost is approximately one-quarter to one-fifth that of andexanet alfa (61). An important safety consideration: certain 4F-PCC formulations contain trace amounts of heparin and are therefore contraindicated in patients with confirmed or strongly suspected heparin-induced thrombocytopenia (HIT). 4F-PCC is recommended as the first-line non-specific agent for DOAC-associated major bleeding and for urgent warfarin reversal (in combination with vitamin K).
Activated Prothrombin Complex Concentrate (aPCC) contains activated factor VII (FVIIa) in addition to non-activated factors II, IX, and X, directly initiating the common coagulation pathway for a more potent hemostatic effect (62). Its use is strictly reserved for breakthrough bleeding in hemophilia patients with inhibitors (63) or as salvage therapy for DOAC-associated bleeding refractory to 4F-PCC. The thrombotic risk with aPCC is considerably higher than with 4F-PCC, particularly when cumulative doses exceed 100 U/kg/d (64).
Fresh Frozen Plasma (FFP) contains the full spectrum of coagulation factors but at low concentrations, necessitating large infusion volumes that predispose patients to transfusion-associated circulatory overload (TACO) and transfusion-related acute lung injury (TRALI) (65, 66). Requirements for ABO compatibility and prolonged thawing further delay correction of coagulopathy relative to 4F-PCC (67). FFP is therefore reserved solely for settings where factor concentrates are unavailable.
2.3.2 Antifibrinolytics: valuable adjuncts, not a solo act
Tranexamic acid (TXA), a synthetic lysine analogue, is the most widely used antifibrinolytic agent, with a robust evidence base supporting its role in traumatic hemorrhage, perioperative bleeding, and as an adjunct in anticoagulant-associated bleeding (68–70). TXA competitively inhibits fibrinolysis by binding to the lysine-binding sites on plasminogen, thereby preventing its conversion to plasmin and stabilizing pre-formed fibrin clots (71). Following intravenous administration, TXA has a half-life of approximately 2 h and provides stable fibrinolytic inhibition for up to 8 h at plasma concentrations of 5–15 mg/L (72, 73). It can be administered intravenously (preferred in acute severe bleeding), orally (for chronic conditions), or topically (for targeted surgical hemostasis) (74, 75).
The clinical efficacy of TXA is firmly established by the CRASH trial program, most notably the CRASH-2 trial (n = 20,211), which demonstrated that early administration (within 3 h of injury) of a 1 g intravenous loading dose followed by 1 g over 8 h significantly reduced all-cause mortality in trauma patients without increasing vascular occlusive events (76–78). Subsequent trials have confirmed its hemostatic benefits in traumatic brain injury, postpartum hemorrhage, and major orthopedic surgery (79–81).
In the context of anticoagulant-associated bleeding, TXA serves strictly as an adjunctive agent. It inhibits hyperfibrinolysis but cannot reverse the pharmacological activity of anticoagulants; therefore, it must never be used as standalone monotherapy for major bleeding. Rather, TXA should be co-administered with specific reversal agents (e.g., idarucizumab) or non-specific procoagulants (e.g., 4F-PCC) (82, 83). Ideally, its use should be guided by objective confirmation of hyperfibrinolysis via viscoelastic hemostatic assays (VHAs) (84). Absolute contraindications include active thromboembolic disease and non-traumatic subarachnoid hemorrhage; the hyperfibrinolytic phase of DIC and severe renal impairment constitute relative contraindications (85).
2.3.3 Other adjunctive agents: limited evidence, niche roles
Several additional hemostatic agents occupy niche roles in certain clinical settings, though their use rests on a limited evidence base and they remain absent from mainstream international guideline recommendations.
Hemocoagulase, a thrombin-like enzyme derived from pit viper venom, promotes local platelet adhesion and hydrolyzes fibrinogen to fibrin at bleeding sites (86). Etamsylate is a synthetic agent that reduces capillary endothelial permeability and enhances platelet adhesion, without demonstrable systemic procoagulant activity (87, 88). Plant-derived formulations such as Yunnan Baiyao exert pleiotropic hemostatic effects through local procoagulant activity, fibrinolytic inhibition, and anti-inflammatory tissue repair (89). All three are used predominantly as empirical adjuncts for capillary or superficial bleeding in perioperative or traumatic settings (90, 91).
The evidence supporting these agents consists almost exclusively of small-sample, single-center observational studies; large-scale randomized controlled trials validating their efficacy and long-term safety are lacking (92–94). Their role in anticoagulant-associated major bleeding remains unsubstantiated, and they should be regarded strictly as empirical adjuncts rather than standard-of-care interventions (Table 3).
Table 3
| Drug class | Specific agent | Mechanism | Key clinical positioning | Key warnings/contraindications |
|---|---|---|---|---|
| Coagulation Factor Concentrates | 4F-PCC | Replenishes vitamin K-dependent factors (II, VII, IX, X); bypasses inhibited steps to restore thrombin generation | First-line non-specific agent for DOAC-associated major bleeding; preferred agent for urgent warfarin reversal (with vitamin K) | Contraindicated in HIT (some formulations contain trace heparin); active thromboembolic disease; hyperfibrinolytic phase of DIC. Evidence largely observational; no RCT data in DOAC-associated bleeding |
| aPCC | Contains activated factor VII (FVIIa); directly initiates common coagulation pathway | Hemophilia A/B with inhibitors; salvage therapy for 4F-PCC-refractory bleeding | Higher thrombotic risk than 4F-PCC, especially >100 U/kg/d; hypercoagulable states; history of thromboembolism | |
| FFP | Replenishes full spectrum of coagulation factors and plasma proteins | Last-resort option when factor concentrates are unavailable | Volume overload; TRALI; ABO incompatibility; slower correction than 4F-PCC | |
| Antifibrinolytic Agents | Tranexamic Acid (TXA) | Competitively inhibits plasminogen activation; stabilizes fibrin clots | Adjunctive therapy (not monotherapy) for anticoagulant-associated bleeding; first-line for major traumatic hemorrhage | Active thromboembolic disease; non-traumatic subarachnoid hemorrhage; use ideally guided by VHA confirmation of hyperfibrinolysis |
| Adjunctive Hemostatic Agents | Hemocoagulase | Promotes local platelet adhesion; converts fibrinogen to fibrin | Empirical adjunct for capillary/superficial bleeding | Limited evidence base (small-sample observational studies); not recommended by mainstream guidelines |
| Etamsylate | Enhances platelet adhesion; reduces capillary endothelial permeability | Empirical adjunct for minor vascular permeability-related bleeding | Limited evidence base; no high-quality studies in anticoagulant-associated major bleeding | |
| Yunnan Baiyao | Pleiotropic: local procoagulant, antifibrinolytic, anti-inflammatory | Empirical adjunct for traumatic and perioperative hemostasis | Limited evidence base; undisclosed formulation; not incorporated into international guidelines |
Comprehensive information comparison of Non-specific hemostatic agents.
3 Bridging the gap: emerging innovations to address current limitations
The preceding section underscored the persistent shortcomings of current hemostatic strategies: narrow target specificity, limited accessibility, prohibitive cost, and, most critically, the thrombotic risks that ultimately led to andexanet alfa's withdrawal. These limitations have spurred the development of next-generation technologies designed to circumvent the constraints of traditional antidotes. The innovations now in the pipeline share a common objective: to deliver safer, more accessible, and on-demand reversibility across the full spectrum of anticoagulant therapies. This section surveys three interconnected frontiers: universal reversal agents and programmable aptamer systems, advanced biologics for refractory bleeding, and companion antidotes purpose-built for novel anticoagulants.
3.1 The quest for a universal antidote and on-demand reversibility
A central limitation of current targeted reversal agents is their narrow specificity—idarucizumab neutralizes only dabigatran, and no clinically available agent broadly covers factor Xa inhibitors, direct thrombin inhibitors, and heparins alike. This gap has driven the search for universal antidotes capable of binding multiple anticoagulant classes with a single molecular entity.
Ciraparantag (95) is the most advanced candidate in this category. A synthetic, water-soluble, cationic small molecule, ciraparantag binds to diverse anticoagulants—including direct factor Xa inhibitors, direct thrombin inhibitors, UFH, and LMWH—through non-covalent hydrogen bonding and charge-charge interactions, sterically preventing their engagement with endogenous coagulation targets (96, 97). In Phase I and II studies, a single intravenous dose of 100 to 300 mg achieved complete reversal of anticoagulant effects within 10 min, with effects sustained for up to 24 h; the agent showed no intrinsic procoagulant activity, with adverse events limited to transient facial flushing and dysesthesia (98). While these early data are promising, ciraparantag has yet to complete Phase III trials, and its clinical profile—including rare safety signals—remains to be fully defined. It is best regarded as a highly promising investigational agent whose ultimate role awaits rigorous evaluation in definitive outcome studies.
A complementary strategy addresses not only breadth of reversal but also the degree of control over the reversal process itself. Nucleic acid aptamer technology offers a fundamentally different paradigm: paired anticoagulant-reversal systems capable of programmable, “light-switch-like” modulation of the coagulation cascade (99). The REG1 system, comprising pegnivacogin (an RNA aptamer targeting factor IXa) and its complementary reversal oligonucleotide anivamersen, enables clinicians to titrate the degree of anticoagulation reversal by adjusting the dose of the reversal agent (100). This platform is particularly suited to short-term, high-intensity anticoagulation scenarios—such as percutaneous coronary intervention (PCI) and cardiopulmonary bypass—where rapid and precisely controllable reversal is essential (101). Compared with monoclonal antibodies and recombinant proteins, nucleic acid aptamers offer lower synthesis costs, minimal immunogenicity, and high structural programmability, providing a viable pathway toward cost-effective, broadly accessible anticoagulant-reversal systems (102, 103). Ongoing research is focused on optimizing in vivo stability and further reducing immunogenicity (Figure 3).
Figure 3
3.2 Next-generation recombinant factors and antibody engineering
For the most severe refractory bleeding scenarios—where both specific and non-specific standard agents prove insufficient—advanced biologic therapies continue to evolve.
Recombinant activated factor VII (rFVIIa) bypasses the need for upstream factor activation by binding directly to tissue factor exposed at sites of vascular injury, generating a localized “thrombin burst” on activated platelet surfaces (104, 105). Although formally approved for hemophilia patients with inhibitors, rFVIIa has assumed a vital salvage role in life-threatening anticoagulant-associated bleeding, massive traumatic hemorrhage, and severe coagulopathy of advanced liver disease—contexts where specific reversal agents are either unavailable or inadequate (106). Its use carries an inherent thrombotic risk, and careful patient selection is essential.
A conceptually distinct bypassing strategy is exemplified by VMX-C001 (107), a modified recombinant variant of human factor X (FX) engineered to resist DOAC-mediated inhibition while retaining full procoagulant activity. Unlike andexanet alfa, which sequesters factor Xa inhibitors, VMX-C001 substitutes for endogenous FX that has been functionally silenced, restoring the common coagulation pathway independently of the specific inhibitor used. In vitro data demonstrate that VMX-C001 completely normalizes DOAC-prolonged clotting times, in contrast to the partial correction achieved by 4F-PCC. The agent is currently under evaluation for surgical reversal in the Equilibrix trial. If clinically validated, VMX-C001 would occupy a distinct niche as a universal FXa DOAC bypassing agent purpose-built for pre-procedural reversal—a scenario for which no dedicated agent is currently approved.
Building on the success and lessons of idarucizumab, monoclonal antibody technology continues to advance toward bispecific and multispecific constructs capable of neutralizing multiple anticoagulant targets via a single molecular entity (108, 109). Concurrently, protein engineering strategies—including PEGylation and amino acid sequence optimization—aim to extend the half-lives of recombinant reversal agents and reduce the need for continuous infusion, directly addressing a key limitation identified in the case of andexanet alfa (110). These innovations remain predominantly preclinical or in early-phase development.
3.3 Companion antidotes for novel anticoagulants
The most consequential lesson of the andexanet alfa experience is that the clinical development of novel anticoagulants must proceed in lockstep with the parallel development of their specific reversal agents. As the pharmacological frontier shifts toward inhibitors of factors upstream in the intrinsic pathway—most notably factor XI (FXI) inhibitors such as milvexian and asundexian, which hold theoretical promise of uncoupling thrombosis prevention from bleeding risk (111)—this lesson assumes heightened urgency. No pharmacological intervention targeting the coagulation cascade can be presumed entirely free of hemorrhagic complications, particularly in the contexts of major trauma or emergency surgery. Accordingly, monoclonal antibodies and small-molecule antagonists targeting FXIa are already under parallel investigation as companion reversal agents (112).
Beyond individual drug-antidote pairs, efforts to improve the accessibility of reversal strategies are equally critical. Research into the refined reconstitution of existing non-specific agents (e.g., targeted modifications of PCCs to approximate the efficacy of specific reversal agents at reduced cost) and the clinical validation of biosimilars and generic small-molecule alternatives such as ciraparantag aim to lower the financial threshold of hemostatic rescue and democratize global access to life-saving interventions (113).
4 Refining clinical practice: integrating evidence, technology, and teamwork
While the emerging technologies surveyed in the preceding section hold considerable promise, the clinician confronting an actively bleeding anticoagulated patient today must act on the basis of imperfect evidence, institutional resource constraints, and time-sensitive physiology. Translating pharmacological knowledge into optimal patient outcomes requires not only familiarity with the available agents but also a structured, systems-level approach to decision-making. This section examines three practical dimensions of clinical care: confronting the evidence gaps that complicate agent selection, implementing a pragmatic, risk-stratified management framework, and navigating the secondary decision of when and how to reinitiate anticoagulation after hemostasis is achieved.
4.1 Confronting the evidence gap: what limits current decision-making
The evidence base underpinning current reversal strategies carries important limitations that directly affect clinical decision-making.
First, recommendations for specific reversal agents are derived predominantly from single-arm trials or indirect comparisons rather than high-quality, head-to-head randomized controlled trials (114). In factor Xa inhibitor-associated major bleeding, multiple systematic reviews have not established the superiority of andexanet alfa over 4F-PCC in reducing hard clinical endpoints such as all-cause mortality (115). This evidence gap is compounded by the absence of empirical data in populations with distinct pharmacokinetic profiles—patients with end-stage renal disease on hemodialysis, pediatric cohorts, and pregnant women—for whom the safety and efficacy of available agents remain largely uncharacterized (116).
Second, the prohibitive cost of specific reversal agents creates substantial access disparities. When andexanet alfa was on the market, its standard treatment course cost approximately five to ten times that of 4F-PCC (117). In primary care facilities and developing nations, the combination of high stocking costs and low usage frequency means these emergency medications are often unavailable at the point of need, substantially eroding the theoretical advantage of targeted reversal in real-world practice (118).
Third, the thrombotic safety signal that led to andexanet alfa's withdrawal serves as the most tangible illustration of the risk inherent in manipulating the coagulation system. The ANNEXA-I trial demonstrated a significantly higher 30-day thrombotic event rate with andexanet alfa compared with usual care (10% vs. 5.6%) (), a finding mechanistically attributed to off-target inhibition of tissue factor pathway inhibitor (TFPI), which removes a critical brake on thrombin generation. This episode has fundamentally reshaped the risk-benefit calculus applied to all emerging reversal agents. Fourth, the evidence supporting 4F-PCC—now the de facto standard for factor Xa inhibitor-associated major bleeding—rests predominantly on observational cohorts rather than randomized comparisons, and its hemostatic mechanism in this setting remains incompletely characterized.
4.2 A pragmatic algorithm for anticoagulant-associated major hemorrhage
Acknowledging these evidence limitations, clinicians nonetheless require an actionable framework for time-sensitive decision-making. The following algorithm (Figure 4) integrates current guideline recommendations, pharmacological principles, and practical considerations of resource availability into a three-tiered approach.
Figure 4
4.2.1 Tier 1: assessment and stratification
The initial step is to distinguish major bleeding from clinically relevant non-major bleeding (CRNMB) using ISTH criteria. Simultaneously, essential pharmacological history must be obtained: the specific anticoagulant agent, the most recent dose and its timing, and the patient's renal function (eGFR), which critically influences residual drug exposure. Where institutional resources permit, conventional laboratory testing should be supplemented with point-of-care viscoelastic hemostatic assays (VHAs; e.g., TEG/ROTEM) or rapid anti-Xa/IIa activity testing to identify whether the hemorrhage is driven solely by anticoagulant accumulation or is compounded by consumptive coagulopathy and hyperfibrinolysis (119, 120).
For CRNMB, conservative management—local hemostatic measures and temporary withholding of subsequent anticoagulant doses—is generally sufficient and avoids exposing the patient to the thrombotic risks of systemic reversal.
4.2.2 Tier 2: pharmacological reversal — current standard of care
For confirmed major hemorrhage, agent selection is dictated by the identified anticoagulant and institutional drug availability.
Dabigatran-associated major bleeding: Idarucizumab, administered as a fixed 5 g intravenous dose (two 2.5 g boluses), is the guideline-recommended first-line reversal strategy based on the RE-VERSE AD trial data (, ).
Factor Xa inhibitor-associated major bleeding: With andexanet alfa no longer available, 4F-PCC is the principal pharmacological option, based on guideline consensus and observational data. Dosed at 25–50 IU/kg depending on institutional protocol, 4F-PCC restores thrombin generation by bypassing the inhibited step in the coagulation cascade (59). Tranexamic acid (TXA) should be co-administered as an adjunct, particularly when hyperfibrinolysis is suspected or confirmed by VHA (84).
Warfarin-associated major bleeding: 4F-PCC, combined with vitamin K, provides rapid hemostasis (via factor replenishment) and sustained reversal (via resumption of endogenous factor synthesis). Vitamin K alone is insufficient for life-threatening hemorrhage due to its slow onset (4–6 h intravenously; ∼24 h orally) ().
Heparin-associated major bleeding: Protamine sulfate, dosed 1:1 to the total heparin administered, achieves complete UFH neutralization within minutes. For LMWH, reversal is partial (approximately 60%), and protamine has no activity against fondaparinux (). Prior to administration, clear documentation of recent heparin exposure must be confirmed, given protamine's paradoxical anticoagulant effect in the absence of circulating heparin.
4.2.3 Tier 3: refractory bleeding and multidisciplinary escalation
For bleeding that remains uncontrolled despite Tier 2 interventions, salvage therapies should be considered. Activated prothrombin complex concentrate (aPCC) or recombinant activated factor VII (rFVIIa) may be deployed, with the recognition that both carry a higher thrombotic risk than 4F-PCC (64, 106).
At this stage, activation of a multidisciplinary “Code Bleed” team is critical. This team should integrate emergency medicine, neurology or surgery (for source control), cardiology (for thrombotic risk stratification), hematology and laboratory medicine (for advanced coagulation monitoring), and clinical pharmacy (for pharmacokinetic assessment and dosing guidance) (, 121).
4.3 Re-initiation of anticoagulation: navigating the secondary risk
Once hemorrhage is controlled, the clinician faces the equally consequential decision of when and how to resume anticoagulation—a determination for which definitive consensus guidelines remain lacking (54). Premature re-initiation risks rebleeding; excessive delay exposes the patient to the original thromboembolic risk for which anticoagulation was prescribed.
A cautious, individualized approach is warranted. Once complete hemostatic stability is confirmed—via neuroimaging in cases of intracranial hemorrhage, or comprehensive clinical assessment in extracranial bleeding—baseline anticoagulation should be resumed as early as clinically feasible, typically within 48–72 h post-hemostasis. Intracranial hemorrhage may warrant a significantly longer deferral. To mitigate recurrent bleeding risk while bridging toward full anticoagulation, re-initiation often begins with a reduced dose or with low-molecular-weight heparin bridging. This calibrated approach aims to protect patients from rebound thromboembolic events—a risk that can be as lethal as the hemorrhage itself (122).
5 Conclusion and future perspectives
The andexanet alfa experience marks a watershed in anticoagulation reversal. Its trajectory—from a landmark in precision pharmacology to a withdrawn product owing to an unacceptable thrombotic risk—has fundamentally recalibrated expectations. The lesson is unequivocal: molecular targeting alone does not confer clinical safety, and surrogate laboratory endpoints such as anti-Xa activity reduction are no substitute for patient-centered outcomes, including mortality and long-term functional recovery.
In the post-andexanet era, the clinical foundation of anticoagulant-associated major bleeding management rests on two agents: idarucizumab for dabigatran reversal and 4F-PCC for factor Xa inhibitor- and warfarin-associated hemorrhage, supported by adjunctive tranexamic acid and, in specific circumstances, protamine sulfate. These agents—accessible, familiar, and supported by decades of real-world experience—remain the practical cornerstones of emergency hemostatic care across most clinical settings globally.
Looking forward, the field is pivoting toward solutions that address the persistent shortcomings of current therapies. Broad-spectrum small molecules such as ciraparantag, if validated in ongoing Phase III trials, may simplify the management of unknown or mixed anticoagulant exposure. Programmable nucleic acid aptamer systems promise a degree of reversibility and control that current agents cannot provide, particularly in short-term, high-intensity anticoagulation scenarios. The parallel development of companion antidotes alongside novel anticoagulants—epitomized by the factor XI inhibitor pipeline—reflects a regulatory and clinical paradigm in which safety infrastructure is no longer an afterthought.
Translating these pharmacological advances into patient benefit will require parallel investment in the systems that surround drug administration. Point-of-care viscoelastic testing, integrated into clinical decision support frameworks, offers a pathway from empirical dosing toward genuinely individualized hemostatic resuscitation. Multidisciplinary “Code Bleed” teams provide the organizational vehicle to deliver this precision at the bedside, particularly for the most critically ill patients.
Ultimately, optimal care of the bleeding anticoagulated patient is not achieved through rigid algorithmic adherence to any single agent or protocol. It demands the continual, judicious balancing of hemorrhagic and thrombotic risks—calibrated to the patient's evolving physiology, the available evidence, and the resources at hand. That equipoise, rather than any individual drug, constitutes the enduring core of clinical wisdom in anticoagulation management.
Statements
Author contributions
WZ: Conceptualization, Methodology, Supervision, Writing – review & editing, Software, Investigation, Writing – original draft, Formal analysis, Project administration, Visualization, Data curation, Resources, Validation. YW: Writing – review & editing, Funding acquisition, Conceptualization, Writing – original draft, Resources, Project administration, Formal analysis, Data curation, Methodology. JL: Writing – review & editing, Data curation, Conceptualization, Project administration. ML: Formal analysis, Data curation, Methodology, Conceptualization, Writing – review & editing. CT: Project administration, Methodology, Writing – review & editing, Formal analysis. ZX: Writing – original draft, Funding acquisition, Writing – review & editing. HL: Conceptualization, Investigation, Methodology, Writing – review & editing, Supervision, Validation, Visualization, Software, Data curation, Funding acquisition, Formal analysis, Project administration, Writing – original draft, Resources.
Funding
The author(s) declared that financial support was received for this work and/or its publication. This study was funded by the Chongqing Bayu Qihuang Scholars Support Programme, Chongqing Yingcai Master and Teacher Programme (CQYC20220203145), Youth Doctoral Incubation Program of the Second Affiliated Hospital of Army Medical University (2023YQB030, 2024YQB007), Postdoctoral Innovation Talents Support Program of the Daping Hospital of Army Medical University (ZXBSH038).
Conflict of interest
The author(s)/remaining author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1.
TranHAMerrimanEBakerRCurnowJYoungLTanCWet al. 2025 Guidelines for direct oral anticoagulants: a practical guidance on the prescription, laboratory testing, peri-operative and bleeding management. Intern Med J. (2025) 55(7):1174–83. 10.1111/imj.70103
2.
MorarasuBCSorodocLMorarasuSMarciucEAHaligaRECeasovschihAet al. Resumption versus discontinuation of direct oral anticoagulation after an episode of gastrointestinal bleeding: a systematic review and meta-analysis of rebleeding episodes. Arch Med Sci. (2025) 21(5):1965–73. 10.5114/aoms/192240
3.
SandhuMReddy GanduAKaur SandhuSSinghHPraneethaDKaur BaathSet al. Real-world comparative bleeding outcomes of direct oral anticoagulants versus warfarin in adults: insights from observational evidence. Blood. (2025) 146:6678. 10.1182/blood-2025-6678
4.
ZhouQLiuXLiuSGuZWuYYangYet al. Effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists in atrial fibrillation patients with liver disease: a systematic review and meta-analysis. Front Pharmacol. (2025) 16:1620394. 10.3389/fphar.2025.1620394
5.
CastellucciLAChenVMKovacsMJLazo-LangnerAGreenstreetPKahnSet al. Bleeding risk with apixaban vs. Rivaroxaban in acute venous thromboembolism. N Engl J Med. (2026) 394(11):1051–60. 10.1056/NEJMoa2510703
6.
KwanHFMahadzirHTumianNRAizuddinANKongSH. Prevalence of Major bleeding in elderly patients on oral anticoagulants for non-valvular atrial fibrillation: a single-center 12-year retrospective review. Geriatrics (Basel). (2025) 10(6):165. 10.3390/geriatrics10060165
7.
WhitworthHBetenskyMBhatRVAl-GhafryMAmankwahEKBissTTet al. Systematic review on the design and methodology of the pediatric direct oral anticoagulant clinical trials for thrombosis prevention: communication from the ISTH SSC subcommittee on pediatric and neonatal thrombosis and hemostasis. J Thromb Haemost. (2026) 24:2303–16. 10.1016/j.jtha.2026.03.011
8.
MorgovanCFrumAStoicescuLButucaADobreaCMArseniuAMet al. An overview of anticoagulant drugs pharmacology, therapeutic approaches, limitations and perspectives. Pharmaceutics. (2026) 18(2):163. 10.3390/pharmaceutics18020163
9.
HermansCVan ThilloQPierceGFMancusoME. Balancing the benefits and risks of rebalancing coagulation in haemophilia. Lancet Haematol. (2026) 13:e261–6. 10.1016/S2352-3026(26)00009-8
10.
CheungKSLeungWK. Gastrointestinal bleeding in patients on novel oral anticoagulants: risk, prevention and management. World J Gastroenterol. (2017) 23(11):1954–63. 10.3748/wjg.v23.i11.1954
11.
HeoYA. Andexanet alfa: first global approval. Drugs. (2018) 78(10):1049–55. 10.1007/s40265-018-0940-4
12.
MoYYamFK. Recent advances in the development of specific antidotes for target-specific oral anticoagulants. Pharmacotherapy. (2015) 35(2):198–207. 10.1002/phar.1532
13.
ChabataCVYuHKeLFrederiksenJWPatelPASullengerBAet al. Andexanet alfa-associated heparin resistance in cardiac surgery: mechanism and in vitro perspectives. Arterioscler Thromb Vasc Biol. (2025) 45(1):144–56. 10.1161/ATVBAHA.124.321650
14.
SiegalDLuGLeedsJMKarbarzMCastilloJMathurVet al. Safety, pharmacokinetics, and reversal of apixaban anticoagulation with andexanet alfa. Blood Adv. (2017) 1(21):1827–38. 10.1182/bloodadvances.2017007112
15.
ConnollySJMillingTJJrEikelboomJWGibsonCMCurnutteJTGoldAet al. Andexanet alfa for acute Major bleeding associated with factor Xa inhibitors. N Engl J Med. (2016) 375(12):1131–41. 10.1056/NEJMoa1607887
16.
MillingTJJrMiddeldorpSXuLKochBDemchukAEikelboomJWet al. Final study report of andexanet alfa for Major bleeding with factor Xa inhibitors. Circulation. (2023) 147(13):1026–38. 10.1161/CIRCULATIONAHA.121.057844
17.
ConnollySJSharmaMCohenATDemchukAMCzłonkowskaALindgrenAGet al. Andexanet for factor Xa inhibitor-associated acute intracerebral hemorrhage. N Engl J Med. (2024) 390(19):1745–55. 10.1056/NEJMoa2313040
18.
YanVKCLiHLWeiLKnappMRJWongICKChanEW. Evolving trends in consumption of direct oral anticoagulants in 65 countries/regions from 2008 to 2019. Drugs. (2023) 83(4):315–40. 10.1007/s40265-023-01837-0
19.
Van GelderICRienstraMBuntingKVCasado-ArroyoRCasoVCrijnsHJGMet al. 2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European association for cardio-thoracic surgery (EACTS). Eur Heart J. (2024) 45(36):3314–414. 10.1093/eurheartj/ehae176
20.
VeltkampRKorompokiEHarveyKHHarveyERFießlerCMalzahnUet al. Direct oral anticoagulants versus no anticoagulation for the prevention of stroke in survivors of intracerebral haemorrhage with atrial fibrillation (PRESTIGE-AF): a multicentre, open-label, randomised, phase 3 trial. Lancet. (2025) 405(10482):927–36. 10.1016/S0140-6736(25)00333-2
21.
De MarcoFValliGAnconaCRuggieriMP. Management of bleeding in patients on direct oral anticoagulants in emergency department: where we are and where we are going. Eur Heart J Suppl. (2023) 25(Suppl C):C15–9. 10.1093/eurheartjsupp/suad004
22.
ReillyPAvan RynJGrottkeOGlundSStangierJ. Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects. Am J Med. (2016) 129(11s):S64–72. 10.1016/j.amjmed.2016.06.007
23.
PollackCVJrReillyPAvan RynJEikelboomJWGlundSBernsteinRAet al. Idarucizumab for dabigatran reversal—full cohort analysis. N Engl J Med. (2017) 377(5):431–41. 10.1056/NEJMoa1707278
24.
CukerABurnettATrillerDCrowtherMAnsellJVan CottEMet al. Reversal of direct oral anticoagulants: guidance from the anticoagulation forum. Am J Hematol. (2019) 94(6):697–709. 10.1002/ajh.25475
25.
van der WallSJvan ReinNvan den BemtBKruipMJHAMeijerKte BoomeLCJet al. Performance of idarucizumab as antidote of dabigatran in daily clinical practice. Europace. (2019) 21(3):414–20. 10.1093/europace/euy220
26.
PollackCVJrReillyPABernsteinRDubielREikelboomJGlundSet al. Design and rationale for RE-VERSE AD: a phase 3 study of idarucizumab, a specific reversal agent for dabigatran. Thromb Haemost. (2015) 114(1):198–205. 10.1160/TH15-03-0192
27.
LevyJHvan RynJSellkeFWReillyPAElsaesserAGlundSet al. Dabigatran reversal with idarucizumab in patients requiring urgent surgery: a subanalysis of the RE-VERSE AD study. Ann Surg. (2021) 274(3):e204–11. 10.1097/SLA.0000000000003638
28.
HaastrupSBHellfritzschMNyboMHvasAMGroveEL. Real-world experience with reversal of dabigatran by idarucizumab. Thromb Res. (2021) 197:179–84. 10.1016/j.thromres.2020.11.010
29.
LevyJHAgenoWChanNCCrowtherMVerhammePWeitzJI. When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost. (2016) 14(3):623–7. 10.1111/jth.13227
30.
JoglarJAChungMKArmbrusterALBenjaminEJChyouJYCroninEMet al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. Circulation. (2024) 149(1):e1–156. 10.1161/CIR.0000000000001193
31.
JarrettJBGimbarRP. Idarucizumab (praxbind) for dabigatran (pradaxa) anticoagulant reversal. Am Fam Physician. (2017) 95(12):798–800.
32.
GlundSMoschettiVNorrisSStangierJSchmohlMRynJvet al. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Thromb Haemost. (2015) 113(5):943–51. 10.1160/TH14-12-1080
33.
GlundSStangierJvan RynJSchmohlMMoschettiVHaazenWet al. Effect of age and renal function on idarucizumab pharmacokinetics and idarucizumab-mediated reversal of dabigatran anticoagulant activity in a randomized, double-blind, crossover phase ib study. Clin Pharmacokinet. (2017) 56(1):41–54. 10.1007/s40262-016-0417-0
34.
BrownKSZahirHGrossoMALanzHJMercuriMFLevyJH. Nonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversal. Crit Care. (2016) 20(1):273. 10.1186/s13054-016-1422-2
35.
AthavaleAJamshidiNRobertsDM. Incomplete responses to the recommended dose of idarucizumab: a systematic review and pharmacokinetic analysis. Clin Toxicol (Phila). (2020) 58(8):789–800. 10.1080/15563650.2020.1743846
36.
EichingerS. Reversing vitamin K antagonists: making the old new again. Hematology Am Soc Hematol Educ Program. (2016) 2016(1):605–11. 10.1182/asheducation-2016.1.605
37.
WallinRHutsonSM. Warfarin and the vitamin K-dependent gamma-carboxylation system. Trends Mol Med. (2004) 10(7):299–302. 10.1016/j.molmed.2004.05.003
38.
DeykinD. Warfarin therapy. 2. N Engl J Med. (1970) 283(15):801–3. 10.1056/NEJM197010082831508
39.
OldenburgJBevansCGMüllerCRWatzkaM. Vitamin K epoxide reductase complex subunit 1 (VKORC1): the key protein of the vitamin K cycle. Antioxid Redox Signal. (2006) 8(3–4):347–53. 10.1089/ars.2006.8.347
40.
StojanovskiBMDi CeraE. Comparative sequence analysis of vitamin K-dependent coagulation factors. J Thromb Haemost. (2022) 20(12):2837–49. 10.1111/jth.15897
41.
ChapmanARYerkeJRLumpkinMRudoniMAMilitelloMWangLet al. Evaluation of response to high-dose intravenous vitamin K administration. Ann Pharmacother. (2023) 57(10):1178–84. 10.1177/10600280231154246
42.
RobinsonDMcFadyenJMerrimanEWeeTCBakerRTranH. Updated recommendations for warfarin reversal in the setting of four-factor prothrombin complex concentrate. Med J Aust. (2025) 222(1):49–51. 10.5694/mja2.52538
43.
GlauserBFSantosGRCSilvaJDTovarAMFPereiraMSVilanovaEet al. Chemical and pharmacological aspects of neutralization of heparins from different animal sources by protamine. J Thromb Haemost. (2018) 16(9):1789–99. 10.1111/jth.14221
44.
DouketisJDSpyropoulosACMuradMHArcelusJIDagerWEDunnASet al. Perioperative management of antithrombotic therapy: an American college of chest physicians clinical practice guideline. Chest. (2022) 162(5):e207–43. 10.1016/j.chest.2022.07.025
45.
ThachilJ. Protamine-The journey from DNA to heparin neutralization to gene therapy. Semin Thromb Hemost. (2022) 48(2):240–3. 10.1055/s-0041-1736574
46.
SmithSA. The cell-based model of coagulation. J Vet Emerg Crit Care (San Antonio). (2009) 19(1):3–10. 10.1111/j.1476-4431.2009.00389.x
47.
HirshJRaschkeR. Heparin and low-molecular-weight heparin: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. (2004) 126(3 Suppl):188s–203. 10.1378/chest.126.3_suppl.188S
48.
van VeenJJMacleanRMHamptonKKLaidlawSKitchenSTothPet al. Protamine reversal of low molecular weight heparin: clinically effective?Blood Coagul Fibrinolysis. (2011) 22(7):565–70. 10.1097/MBC.0b013e3283494b3c
49.
BaglinTBarrowcliffeTWCohenAGreavesM. Guidelines on the use and monitoring of heparin. Br J Haematol. (2006) 133(1):19–34. 10.1111/j.1365-2141.2005.05953.x
50.
HirshJWarkentinTEShaughnessySGAnandSSHalperinJLRaschkeRet al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. (2001) 119(1 Suppl):64s–94. 10.1378/chest.119.1_suppl.64S
51.
LevyJHGhadimiKKizhakkedathuJNIbaT. What’s fishy about protamine? Clinical use, adverse reactions, and potential alternatives. J Thromb Haemost. (2023) 21(7):1714–23. 10.1016/j.jtha.2023.04.005
52.
ButterworthJLinYAPrielippRBennettJJamesR. The pharmacokinetics and cardiovascular effects of a single intravenous dose of protamine in normal volunteers. Anesth Analg. (2002) 94(3):514–22; Table of contents. 10.1097/00000539-200203000-00008
53.
BouzatPCharbitJAbbackP-SHuet-GarrigueDDelhayeNLeoneMet al. Efficacy and safety of early administration of 4-factor prothrombin Complex concentrate in patients with trauma at risk of massive transfusion: the PROCOAG randomized clinical trial. Jama. (2023) 329(16):1367–75. 10.1001/jama.2023.4080
54.
TomaselliGFMahaffeyKWCukerADobeshPPDohertyJUEikelboomJWet al. 2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology solution set oversight committee. J Am Coll Cardiol. (2020) 76(5):594–622. 10.1016/j.jacc.2020.04.053
55.
MoiaMSquizzatoA. Reversal agents for oral anticoagulant-associated major or life-threatening bleeding. Intern Emerg Med. (2019) 14(8):1233–9. 10.1007/s11739-019-02177-2
56.
HoodCGoldsteinJNMillingTJRefaaiMABajcicPGoldsteinBet al. INR And vitamin K-dependent factor levels after vitamin K antagonist reversal with 4F-PCC or plasma. Blood Adv. (2023) 7(10):2206–13. 10.1182/bloodadvances.2022009015
57.
TanakaKAShettarSVandyckKSheaSMAbuelkasemE. Roles of four-factor prothrombin Complex concentrate in the management of critical bleeding. Transfus Med Rev. (2021) 35(4):96–103. 10.1016/j.tmrv.2021.06.007
58.
SchwebachAAWaybrightRAJohnsonTJ. Fixed-Dose four-factor prothrombin Complex concentrate for vitamin K antagonist reversal: does one dose fit all?Pharmacotherapy. (2019) 39(5):599–608. 10.1002/phar.2261
59.
FerreiraLOOldemburgRALLeitão FilhoJMCerveiraRAVasconcelosVWda CostaGEet al. Andexanet alfa versus four-factor prothrombin Complex concentrate for the reversal of factor Xa (FXa) inhibitor-associated intracranial hemorrhage: a systematic review of retrospective studies. J Clin Med. (2024) 13(11):3077. 10.3390/jcm13113077
60.
PuchsteinDKorkFSchöchlHRayatdoostFGrottkeO. 3-Factor Versus 4-factor prothrombin Complex concentrates for the reversal of vitamin K antagonist-associated coagulopathy: a systematic review and meta-analysis. Thromb Haemost. (2023) 123(1):40–53. 10.1055/s-0042-1758653
61.
BarraMEDasASHayesBDRosenthalESRosovskyRPFuhLet al. Evaluation of andexanet alfa and four-factor prothrombin complex concentrate (4F-PCC) for reversal of rivaroxaban- and apixaban-associated intracranial hemorrhages. J Thromb Haemost. (2020) 18(7):1637–47. 10.1111/jth.14838
62.
MartinKMaADKeyNS. Chapter 15—molecular basis of hemostatic and thrombotic diseases. In: ColemanWBTsongalisGJ, editors. Essential Concepts in Molecular Pathology. 2nd ed.Chapel Hill: Academic Press (2020). p. 229–46.
63.
SrivastavaASantagostinoEDougallAKitchenSSutherlandMPipeSWet al. WFH Guidelines for the management of hemophilia, 3rd edition. Haemophilia. (2020) 26(Suppl 6):1–158. 10.1111/hae.14046
64.
OwenEJGibsonGAHumanTWolfeR. Thromboembolic complications after receipt of prothrombin Complex concentrate. Hosp Pharm. (2021) 56(6):709–13. 10.1177/0018578720946754
65.
DesboroughMSanduRBrunskillSJDoreeCTrivellaMMontedoriAet al. Fresh frozen plasma for cardiovascular surgery. Cochrane Database Syst Rev. (2015) 2015(7):Cd007614. 10.1002/14651858.CD007614.pub2
66.
SokouRParastatidouSKonstantinidiATsantesAGIacovidouNDoxaniCet al. Fresh frozen plasma transfusion in the neonatal population: a systematic review. Blood Rev. (2022) 55:100951. 10.1016/j.blre.2022.100951
67.
Chai-AdisaksophaCHillisCSiegalDMMovillaRHeddleNIorioAet al. Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal. A systematic review and meta-analysis. Thromb Haemost. (2016) 116(5):879–90. 10.1160/TH16-04-0266
68.
Al-SamkariHShinKCardoniLPighettiEHRitsSMcMahonLet al. Antifibrinolytic agents for hemoptysis management in adults with cystic fibrosis. Chest. (2019) 155(6):1226–33. 10.1016/j.chest.2019.02.010
69.
KerKRobertsIShakurHCoatsTJ. Antifibrinolytic drugs for acute traumatic injury. Cochrane Database Syst Rev. (2015) 2015(5):Cd004896. 10.1002/14651858.CD004896.pub4
70.
SangYMenegattiMBrodyJAWigginsKLCooleyBCKapferKNet al. Plasminogen activation and plasmin activity are not necessary to prevent venous thrombosis/thromboembolism. Blood. (2025) 146(11):1346–58. 10.1182/blood.2025028680
71.
ChenTLiuDGuYGaoTLiXLengX. Unraveling the neurotoxic mechanisms of tranexamic acid in epilepsy induction: a network toxicology and molecular docking approach. BMC Med. (2026) 24(1):67. 10.1186/s12916-025-04605-x
72.
Grassin-DelyleSSemeraroMLamyEUrienSRungeIFoissacFet al. Pharmacokinetics of tranexamic acid after intravenous, intramuscular, and oral routes: a prospective, randomised, crossover trial in healthy volunteers. Br J Anaesth. (2022) 128(3):465–72. 10.1016/j.bja.2021.10.054
73.
MeretojaAYassiNWuTYChurilovLSiboltGJengJ-Set al. Tranexamic acid in patients with intracerebral haemorrhage (STOP-AUST): a multicentre, randomised, placebo-controlled, phase 2 trial. Lancet Neurol. (2020) 19(12):980–7. 10.1016/S1474-4422(20)30369-0
74.
MazzeiMDonohueJKSchreiberMRowellSGuyetteFXCottonBet al. Prehospital tranexamic acid is associated with a survival benefit without an increase in complications: results of two harmonized randomized clinical trials. J Trauma Acute Care Surg. (2024) 97(5):697–702. 10.1097/TA.0000000000004315
75.
RowellSMeierENHoyos GomezTFlemingMJuiJMorrisonLet al. The effects of prehospital TXA on mortality and neurologic outcomes in patients with traumatic intracranial hemorrhage: a subgroup analysis from the prehospital TXA for TBI trial. J Trauma Acute Care Surg. (2024) 97(4):572–80. 10.1097/TA.0000000000004354
76.
PatelPAWyrobekJAButwickAJPivalizzaEGHareGMTMazerCDet al. Update on applications and limitations of perioperative tranexamic acid. Anesth Analg. (2022) 135(3):460–73. 10.1213/ANE.0000000000006039
77.
NutbeamTRobertsIWeekesLShakur-StillHBrennerAAgeronFX. Use of tranexamic acid in major trauma: a sex-disaggregated analysis of the clinical randomisation of an antifibrinolytic in significant haemorrhage (CRASH-2 and CRASH-3) trials and UK trauma registry (trauma and audit research network) data. Br J Anaesth. (2022) 129(2):191–9. 10.1016/j.bja.2022.03.032
78.
RobertsIShakurHCoatsTHuntBBalogunEBarnetsonLet al. The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients. Health Technol Assess. (2013) 17(10):1–79. 10.3310/hta17100
79.
The CRASH-3 trial collaborators. Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial. Lancet. (2019) 394(10210):1713–23. 10.1016/S0140-6736(19)32233-0
80.
AcharyaPAminANallamotuSRiazCZKurubaVSenthilkumarVet al. Prehospital tranexamic acid in trauma patients: a systematic review and meta-analysis of randomized controlled trials. Front Med (Lausanne). (2023) 10:1284016. 10.3389/fmed.2023.1284016
81.
ZhangL-KMaJ-XKuangM-JZhaoJWangYLuBet al. Comparison of oral versus intravenous application of tranexamic acid in total knee and hip arthroplasty: a systematic review and meta-analysis. Int J Surg. (2017) 45:77–84. 10.1016/j.ijsu.2017.07.097
82.
VeltkampRPurruckerJ. Management of spontaneous intracerebral hemorrhage. Curr Neurol Neurosci Rep. (2017) 17(10):80. 10.1007/s11910-017-0783-5
83.
EtruscoABarraFChianteraVFerreroSBoglioloSEvangelistiGet al. Current medical therapy for adenomyosis: from bench to bedside. Drugs. (2023) 83(17):1595–611. 10.1007/s40265-023-01957-7
84.
MooreEEMooreHBKornblithLZNealMDHoffmanMMutchNJet al. Trauma-induced coagulopathy. Nat Rev Dis Primers. (2021) 7(1):30. 10.1038/s41572-021-00264-3
85.
TengbornLBlombäckMBerntorpE. Tranexamic acid–an old drug still going strong and making a revival. Thromb Res. (2015) 135(2):231–42. 10.1016/j.thromres.2014.11.012
86.
GreenD. Hematology products from snake venoms. Thromb Res. (2025) 245:109215. 10.1016/j.thromres.2024.109215
87.
Cobo-NuñezMYEl AssarMCuevasPSánchez-FerrerAMartínez-GonzálezJRodríguez-MañasLet al. Haemostatic agent etamsylate in vitro and in vivo antagonizes anti-coagulant activity of heparin. Eur J Pharmacol. (2018) 827:167–72. 10.1016/j.ejphar.2018.03.028
88.
TarasekDGąsowska-BajgerBWojtasekH. Mechanisms of interference of p-diphenols with the trinder reaction. Bioorg Chem. (2020) 97:103692. 10.1016/j.bioorg.2020.103692
89.
QianHZhangWZhangMMaSZhenMHeHet al. Yunnan baiyao (YNBY): pharmacological mechanisms, therapeutic applications, and clinical evidence. Front Pharmacol. (2025) 16:1589035. 10.3389/fphar.2025.1589035
90.
MaWZhaoTYuLLiuWWangHZhaoP. Incidence, clinical features, and risk factors of hemocoagulase-induced hypofibrinogenemia: a retrospective real-world study. Medicine (Baltimore). (2024) 103(15):e37773. 10.1097/MD.0000000000037773
91.
XuBWuYLiuDGengYLiXLiaoGet al. Nanoclay-Triggered in situ self-gelling yam microparticles via coagulation activation for robust wet tissue adhesion and instant hemostasis. ACS Appl Mater Interfaces. (2025) 17(51):69054–68. 10.1021/acsami.5c18393
92.
CarlinSCukerAGattAGendronNHernández-GeaVMeijerKet al. Anticoagulation for stroke prevention in atrial fibrillation and treatment of venous thromboembolism and portal vein thrombosis in cirrhosis: guidance from the SSC of the ISTH. J Thromb Haemost. (2024) 22(9):2653–69. 10.1016/j.jtha.2024.05.023
93.
WeiJ-MZhuM-WZhangZ-TJiaZ-GHeX-DWanY-Let al. A multicenter, phase III trial of hemocoagulase agkistrodon: hemostasis, coagulation, and safety in patients undergoing abdominal surgery. Chin Med J (Engl). (2010) 123(5):589–93. 10.3760/cma.j.issn.0366-6999.2010.05.016
94.
LiuYDongCHeXWuPShuYChenL. Severe hematuria in a patient receiving bevacizumab and pembrolizumab for metastatic cervical cancer: a case report. BMC Nephrol. (2023) 24(1):51. 10.1186/s12882-023-03101-9
95.
ChanNCWeitzJI. Ciraparantag as a potential universal anticoagulant reversal agent. Eur Heart J. (2022) 43(10):993–5. 10.1093/eurheartj/ehab706
96.
AnsellJLaulichtBEBakhruSHBurnettAJiangXChenLet al. Ciraparantag, an anticoagulant reversal drug: mechanism of action, pharmacokinetics, and reversal of anticoagulants. Blood. (2021) 137(1):115–25. 10.1182/blood.2020007116
97.
van EsNDe CaterinaRWeitzJI. Reversal agents for current and forthcoming direct oral anticoagulants. Eur Heart J. (2023) 44(20):1795–806. 10.1093/eurheartj/ehad123
98.
CarbajoDPérezYCasteloGFPratsEBujonsJAlfonsoI. Efficient small-molecule reversal agents for anticoagulant fondaparinux. ACS Pharmacol Transl Sci. (2025) 8(5):1333–46. 10.1021/acsptsci.4c00747
99.
LincoffAMMehranRPovsicTJZelenkofskeSLHuangZArmstrongPWet al. Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial. Lancet. (2016) 387(10016):349–56. 10.1016/S0140-6736(15)00515-2
100.
PovsicTJVavalleJPAlexanderJHAberleLHZelenkofskeSLBeckerRCet al. Use of the REG1 anticoagulation system in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the phase II RADAR-PCI study. EuroIntervention. (2014) 10(4):431–8. 10.4244/EIJY14M06_01
101.
LiLXuSYanHLiXYazdHSLiXet al. Nucleic acid aptamers for molecular diagnostics and therapeutics: advances and perspectives. Angew Chem Int Ed Engl. (2021) 60(5):2221–31. 10.1002/anie.202003563
102.
PovsicTJVavalleJPAberleLHKasprzakJDCohenMGMehranRet al. A phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial. Eur Heart J. (2013) 34(31):2481–9. 10.1093/eurheartj/ehs232
103.
KrissanaprasitAKeyCMFroehlichKPontulaSMihalkoEDupontDMet al. Multivalent aptamer-functionalized single-strand RNA origami as effective, target-specific anticoagulants with corresponding reversal agents. Adv Healthc Mater. (2021) 10(11):e2001826. 10.1002/adhm.202001826
104.
HednerU. Recombinant activated factor VII: 30 years of research and innovation. Blood Rev. (2015) 29(Suppl 1):S4–8. 10.1016/S0268-960X(15)30002-3
105.
HednerU. Recombinant coagulation factor VIIa: from the concept to clinical application in hemophilia treatment in 2000. Semin Thromb Hemost. (2000) 26(4):363–6. 10.1055/s-2000-8453
106.
YuLYangDChuMSunY. Advances and challenges in the purification of recombinant coagulation factors: a review. J Chromatogr A. (2024) 1716:464662. 10.1016/j.chroma.2024.464662
107.
NagyMGomesTvan OerleRHackengTMMagdelijnsFJHHenskensYMCet al. Coagulation assays for assessing the bypassing of factor Xa direct oral anticoagulants using VMX-C001. Res Pract Thromb Haemost. (2026) 10(2):103375. 10.1016/j.rpth.2026.103375
108.
De Pablo-MorenoJASerranoLJRevueltaLSánchezMJLirasA. The vascular endothelium and coagulation: homeostasis, disease, and treatment, with a focus on the Von willebrand factor and factors VIII and V. Int J Mol Sci. (2022) 23(15):8283. 10.3390/ijms23158283
109.
BurnessCB. Idarucizumab: first global approval. Drugs. (2015) 75(18):2155–61. 10.1007/s40265-015-0508-5
110.
FavresseJHardyMvan DievoetMASennesaelALDouxfilsJSamamaCMet al. Andexanet alfa for the reversal of factor Xa inhibitors. Expert Opin Biol Ther. (2019) 19(5):387–97. 10.1080/14712598.2019.1599355
111.
CapodannoDAlexanderJHBahitMCEikelboomJWGibsonCMGoodmanSGet al. Factor XI inhibitors for the prevention and treatment of venous and arterial thromboembolism. Nat Rev Cardiol. (2025) 22(11):896–912. 10.1038/s41569-025-01144-z
112.
SarichTCSeltzerJHBerkowitzSDCostin'JCurnutteJTGibsonCMet al. Novel oral anticoagulants and reversal agents: considerations for clinical development. Am Heart J. (2015) 169(6):751–7. 10.1016/j.ahj.2015.03.010
113.
BatesJTKellyCWLaneJE. Low-Cost model for battlefield wound and hemorrhage training. Mil Med. (2023) 188(7–8):e1478–82. 10.1093/milmed/usab556
114.
CostaOSConnollySJSharmaMBeyer-WestendorfJChristophMJLovelaceBet al. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis. Crit Care. (2022) 26(1):180. 10.1186/s13054-022-04043-8
115.
AbdulrehmanJEikelboomJWSiegalDM. Andexanet alfa for reversal of factor Xa inhibitors: a critical review of the evidence. Future Cardiol. (2019) 15(6):395–404. 10.2217/fca-2019-0038
116.
GoldinMTsaftaridisNJnaniJSpyropoulosAC. Reversal of direct oral anticoagulants (DOACs) for critical bleeding or urgent procedures. J Clin Med. (2025) 14(3):1013. 10.3390/jcm14031013
117.
FanikosJGoldsteinJNLovelaceBBeaubrunACBlissettRSAragãoF. Cost-effectiveness of andexanet alfa versus four-factor prothrombin complex concentrate for the treatment of oral factor Xa inhibitor-related intracranial hemorrhage in the US. J Med Econ. (2022) 25(1):309–20. 10.1080/13696998.2022.2042106
118.
SobolewskiKABrophyAChoiSCOpshaY. Real-World observational review of andexanet alfa prescribing and utilization outcomes at a community teaching hospital. Crit Care Explor. (2021) 3(4):e0356. 10.1097/CCE.0000000000000356
119.
AmiralJDunoisCAmiralCSeghatchianJ. Anti-Xa bioassays for the laboratory measurement of direct factor Xa inhibitors in plasma, in selected patients. Transfus Apher Sci. (2016) 55(2):249–61. 10.1016/j.transci.2016.09.003
120.
DiasJDSauaiaAAchneckHEHartmannJMooreEE. Thromboelastography-guided therapy improves patient blood management and certain clinical outcomes in elective cardiac and liver surgery and emergency resuscitation: a systematic review and analysis. J Thromb Haemost. (2019) 17(6):984–94. 10.1111/jth.14447
121.
NataliniDXhemalajRCarelliS. Viscoelastic hemostatic assays in the management of trauma-induced coagulopathy: a clinical update. J Clin Med. (2025) 15(1):12. 10.3390/jcm15010012
122.
BaughCWLevineMCornuttDWilsonJWKwunRMahanCEet al. Anticoagulant reversal strategies in the emergency department setting: recommendations of a multidisciplinary expert panel. Ann Emerg Med. (2020) 76(4):470–85. 10.1016/j.annemergmed.2019.09.001
Summary
Keywords
anticoagulants, clinical decision support, hemorrhage, point-of-Care systems, precision medicine, prothrombin complex concentrates, reversal agents
Citation
Zheng W, Wang Y, Lu J, Long M, Tang C, Xu Z and Li H (2026) From empirical hemostasis to precision reversal: clinical challenges, technological innovations, and individualized strategies in anticoagulant-associated bleeding. Front. Cardiovasc. Med. 13:1846208. doi: 10.3389/fcvm.2026.1846208
Received
02 April 2026
Revised
29 May 2026
Accepted
08 June 2026
Published
25 June 2026
Volume
13 - 2026
Edited by
Alex Spyropoulos, Hofstra University, United States
Reviewed by
Istvan Zatroch, Semmelweis University, Hungary
Elizabeth Uttaro, University of Rochester, United States
Updates
Copyright
© 2026 Zheng, Wang, Lu, Long, Tang, Xu and Li.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Zihui Xu zihuixu@tmmu.edu.cn Han Li lihan@tmmu.edu.cn
† These authors have contributed equally to this work and share first authorship
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.